Caris Life Sciences Financials - Benzinga

Caris Life Sciences Inc

CAINASDAQ

Trade with Public

Trade with Public

$32.27

0.621.96%

近くで: Sep 24, 5:00 PM EST

$32.27

N/A

時間外: 4:00 PM EST

概要ニュース業績予想イベント目標株価財務センチメント株主構成配当比較オプション株式レポート

Caris Life Sciences Financials

Caris Life Sciences (CAI) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Caris Life Sciences Raises FY2026 Sales Guidance from $1.000B-$1.020B to $1.030B-$1.040B vs $1.003B Est

Caris Life Sciences (NASDAQ:CAI) raises FY2026 sales outlook from $1.000 billion-$1.020 billion to $1.030 billion-$1.040 billion vs $1.003 billion estimate.

Benzinga Newsdesk

PRO
Caris Life Sciences Q2 Sales $263.712M Beat $238.125M Estimate

Benzinga Newsdesk

PRO
Caris Life Sciences Affirms FY2026 Sales Guidance of $1.000B-$1.020B vs $1.007B Est

Caris Life Sciences (NASDAQ:CAI) affirms FY2026 sales outlook from $1.000 billion-$1.020 billion to $1.000 billion-$1.020 billion vs $1.007 billion estimate.

Benzinga Newsdesk

PRO
Caris Life Sciences Q1 Sales $216.174M Beat $210.292M Estimate

Caris Life Sciences (NASDAQ:CAI) reported quarterly sales of $216.174 million which beat the analyst consensus estimate of $210.292 million by 2.80 percent. This is a 78.78 percent increase over sales of $120.915

Benzinga Newsdesk

These Analysts Revise Their Forecasts On Caris Life Sciences Following Q4 Earnings

Avi Kapoor

Cancer Test Maker Caris Life Sciences Unveils Breakthrough In Early Cancer Detection, Profit Surprise

Caris Life Sciences stock jumps after earnings crush estimates, sales soar 125%, and cancer test data show strong early results.

Vandana Singh

© 2026 Benzinga | All Rights Reserved